Using placebo in hypertension clinical trials: New information and new opportunities

Journal of Human Hypertension

Volumn 22, Issue 10, 2008, Pages 653-655

  Weber, M A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INFORMED CONSENT; MEDICAL ETHICS; NOTE; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; RISK BENEFIT ANALYSIS; RISK REDUCTION;

CONTROL GROUPS; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; PLACEBOS; REPRODUCIBILITY OF RESULTS;

EID: 52749098522     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.53     Document Type: Note

References (15)

1. DeFelicie A, Willard J, Lawrence J, Hung J, Gordon M, Karkowsky A et al. The risks associated with short-term placebo-controlled anti-hypertensive clinical trials: A descriptive meta-analysis. J Hum Hypertension 2008, in press.
2. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, deFaire U, et al., for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 996-1003.
3. Julius S, Kjeldsen SE, Weber MA, Brunner HR, Ekman S, Hansson L, et al., VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
4. The ALLHAT Officers. Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
6. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al., for the systolic hypertension in Europe (Syst-Eur) trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
7. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L et al Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051.
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC7 Report. JAMA 2003; 289: 2560-2572.
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Task force for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
11. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al., for the HOT study group. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
12. UK Prospective Diabetes Study Group. efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
13. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomized trials. Lancet 2003; 362: 1527-1535.
14. Weber MA. The ethics of using placebo in hypertension clinical trials. J Hypertens 1999; 17: 5-8.
15. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandanavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet 2005; 366: 895-906.